Insulet CorporationNasdaq: PODD
Health Care · Health Care Equipment
$174.86
+1.58%
Vol: 1.0M
Research Digest
Friday, May 1, 2026
Redburn downgrades to Neutral citing eroding moats; Q1 earnings May 6, safety advisory April 29
Insulet downgraded by Redburn (Rothschild) April 24 to Neutral from Buy, target cut to $220 from $380 citing eroding distribution/product moats and elevated expectations. Company issued safety advisory April 29 on affected pod lots; clarified 29 confirmed serious adverse events. Shares surged 7.6% April 30 to $172.14. Strong analyst sentiment overall with consensus Buy and $360 PT (87% upside). Guiding Q1 revenue growth 25-27%, FY 20-22%. Q1 earnings due May 6. Downside risk: regulatory headwinds on device correction.
Previous Market Intelligence
13 daysApr 30Insulet reports Q1 earnings beat amid safety recall concerns and analyst downgradesMixed▶
Insulet Corp beat Q1 earnings with $784M in sales (+29% constant currency), but the voluntary recall of Omnipod 5 lots due to manufacturing issues affecting 476 serious injuries has pressured the stock to a 52-week low of $177.81. Rothschild Redburn downgraded to Neutral citing competitive pressure from hybrid patch devices, while Bernstein and Oppenheimer maintain Outperform ratings with price targets at $330 and $300 respectively. The company will present at BofA Securities Health Care Conference on May 13. With 87% upside potential and EPS growth expected at 27.44%, the market sentiment remains mixed despite valuation concerns.
Apr 16Insulet faces securities fraud lawsuit over Omnipod 5 defect disclosure; stock down 11% YTD 2026Negative▶
Insulet disclosed voluntary medical device correction on March 12, 2026 for Omnipod 5 insulin pods due to design defect causing potential insulin leakage. 18 serious adverse events linked to the defect affecting about 1.5% of annual production. Class action securities fraud lawsuit initiated investigating whether company concealed defect prior to disclosure. Stock hit 52-week low of $202.44 on April 2 and down over 11% in 2026. Despite legal challenges, analyst consensus remains bullish with 90%+ of covering analysts maintaining Buy ratings and price target of $360 implying 77.63% upside.
Apr 15Insulet recalled Omnipod 5 insulin pods due to design defect; stock down 6.9% but analysts project 77.63% upside.Mixed▶
Insulet Corporation disclosed on March 12 a voluntary medical device correction for Omnipod 5 insulin pods due to design defect causing potential insulin leakage, affecting 1.5% of annual production with 18 linked serious adverse events. Despite the recall, FY2025 revenue reached $2.7B (+30% YoY) with gross margin 71.6%. Analyst consensus: 21 recommend Buy (Strong Buy) with $349.8 average PT, implying 77.63% upside.
Apr 14Insulet down 16% from year-ago lows after Omnipod 5 pod design defect disclosure; 90%+ analysts maintain Buy.Negative▶
Insulet Corporation faces headwinds from voluntary medical device correction for Omnipod 5 insulin pods due to design defect causing insulin leakage. Stock down 11% YTD and hit 52-week low. Despite weakness, 90%+ of covering analysts maintain bullish ratings with $360 consensus price target implying 75% upside. Management projects 21-23% Omnipod revenue growth 2026.
Apr 13Insulet announces voluntary Omnipod 5 device correction for design defect, but analyst sentiment remains bullish with 75% upside potential.Mixed▶
Insulet disclosed a voluntary correction of Omnipod 5 insulin pods due to a design defect that could cause insulin leakage, with eighteen serious adverse events. Despite the device issue, over 90% of analysts maintain bullish ratings, citing strong demand for tubeless insulin pumps. Goldman Sachs initiated Buy coverage on April 8.
Apr 10Insulet shares down 16% YTD; Omnipod 5 device correction under investigation but analysts maintain 75% upside consensus.Mixed▶
Insulet faces headwinds from a March 12 voluntary Omnipod 5 insulin pod correction due to design defect causing potential insulin leakage. Citi downgraded to Neutral from Buy on April 7. Legal investigation commenced by Levi & Korsinsky. Over 90% of analysts remain bullish with $360 consensus target (75% upside). Company appointed Mike Panos as Chief Commercial Officer.
Apr 9Insulet reports strong 2025 growth with 31% revenue expansion, launches Omnipod in Middle EastPositive▶
Insulet reported robust 2025 growth with revenue reaching approximately $2.7 billion (+31% growth). Company announced $350 million increase to share repurchase authorization and provided mid-20s revenue growth guidance for 2026. Presented EVOLUTION 2 feasibility study results for investigational Omnipod fully closed-loop automated insulin delivery system with 68% average time in range (24% improvement vs injection). Launched Omnipod 5 and Omnipod Discover platform in Middle East (Saudi Arabia, Kuwait, Qatar, UAE). Q1 2026 earnings due May 6, 2026. Omnipod 5 now available in 19 countries with planned launches in Spain (2026) and Greece/Croatia (1H 2027). Analysts rate PODD as Buy with $352.25 price target (+73.99% upside).
Apr 8Insulet Appoints Mike Panos as Chief Commercial Officer; Strong Revenue Growth MomentumPositive▶
Insulet appointed Mike Panos as Chief Commercial Officer to enhance commercial strategy. Q4 revenue reached $784 million, up 29% in constant currency, surpassing estimates of $768 million. 2025 total revenue about $2.7B with 31% growth, gross margin 71.6%, operating margin 17.5%. Stock down 20.6% YoY but analyst consensus Buy with $352.25 average price target, 73.99% upside.
Apr 7No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 6Insulet voluntary device correction for Omnipod 5 affecting 1.5% of production.Mixed▶
Insulet disclosed voluntary medical device correction for Omnipod 5 insulin pods on March 12, 2026 due to design defect causing insulin leakage linked to 18 serious adverse events. Affected pods represent 1.5% of annual production. Q1 2026 earnings May 6. Avg Strong Buy PT $357.65.
Apr 3Insulet appoints Mike Panos as Chief Commercial Officer amid ongoing litigation over Omnipod 5 device defect recall.Negative▶
Insulet Corporation appointed Mike Panos as EVP and Chief Commercial Officer on April 1, 2026. The company continues to face investor lawsuits following a March 12, 2026 voluntary medical device correction for Omnipod 5 insulin pods due to design defects that could cause insulin leakage. Pomerantz LLP and other law firms are investigating claims.
Apr 2Insulet initiates voluntary medical device correction for Omnipod 5 pods affecting 1.5% of annual production; 18 serious adverse events reported.Negative▶
Insulet initiated voluntary correction for specific Omnipod 5 Pod lots (1.5% of annual production) due to potential tubing tears causing insulin leakage. 18 serious adverse events reported including hospitalizations and diabetic ketoacidosis (DKA). Stock declined ~6.9% on March 12, 2026 disclosure. Q1 2026 earnings scheduled May 6. Despite correction, Insulet reported strong Q4 with better-than-expected earnings and 26.8% revenue growth. 20 analysts rate Strong Buy with PT $357.65 (+72.74%). Correction viewed as manageable issue by some analysts.
Apr 1Insulet faces device correction for Omnipod 5 affecting 1.5% of annual production with 18 serious adverse events.Mixed▶
Insulet initiated a voluntary Medical Device Correction on March 12 for specific Omnipod 5 Pod lots after internal tubing tears caused potential insulin leaks. 18 serious adverse events including hospitalization and DKA reported with no deaths. Despite setback, Q4 2025 revenue of $783.8M (+31.2%).
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| PODDINSULET | $174.86 | +1.58% | -15.4% | 21.3x | 1.47 | $11.9B |
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.